Investor Alert: Robbins LLP Informs Investors of the Savara Inc. Class Action Lawsuit

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 8, 2025 /PRNewswire/ -- Robbins LLPÂ informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Savara Inc. (NASAQ: SVRA) securities between March 7, 2024 and May 23, 2025. Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony- ...